Icagen (Nasdaq: ICGN) may resume clinical trials of a proposed treatment for epilepsy after the Food and Drug Administration removed a clinical hold on its development.

Trials were stopped last year following an incident with a patient.

Icagen submitted additional clinical trial information and a proposal for a Phase II clinical trial to the FDA. The FDA’s decision was announced Wednesday.

“We are pleased with the FDA’s action and will shortly be determining the next steps in the clinical development of our epilepsy drug candidate, ICA-105665,” Icagen Chief Executive Officer P. Kay Wagoner said in a statement.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.